These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 20190365)

  • 21. [Effects of SERMs on bone health. Discrimination of SERMs from bisphosphonates in the treatment of postmenopausal osteoporosis].
    Iwamoto J
    Clin Calcium; 2010 Mar; 20(3):396-407. PubMed ID: 20190370
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effect of hormone replacement, alendronate, or combination therapy on hip structural geometry: a 3-year, double-blind, placebo-controlled clinical trial.
    Greenspan SL; Beck TJ; Resnick NM; Bhattacharya R; Parker RA
    J Bone Miner Res; 2005 Sep; 20(9):1525-32. PubMed ID: 16059624
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Relationships between bone mineral density and incident vertebral fracture risk with raloxifene therapy.
    Sarkar S; Mitlak BH; Wong M; Stock JL; Black DM; Harper KD
    J Bone Miner Res; 2002 Jan; 17(1):1-10. PubMed ID: 11771654
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Sequential treatment of severe postmenopausal osteoporosis after teriparatide: final results of the randomized, controlled European Study of Forsteo (EUROFORS).
    Eastell R; Nickelsen T; Marin F; Barker C; Hadji P; Farrerons J; Audran M; Boonen S; Brixen K; Gomes JM; Obermayer-Pietsch B; Avramidis A; Sigurdsson G; Glüer CC
    J Bone Miner Res; 2009 Apr; 24(4):726-36. PubMed ID: 19049337
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Anabolic therapy for osteoporosis.
    Bilezikian JP
    Int J Fertil Womens Med; 2005; 50(2):53-60. PubMed ID: 16334411
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Evaluation of the sexual function and quality of life in raloxifene treated postmenopausal women.
    Biri A; Korucuoglu U; Ilhan MN; Ciftci B; Bozkurt N; Guner H
    Arch Gynecol Obstet; 2009 Apr; 279(4):505-9. PubMed ID: 18690468
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Raloxifene reverses bone loss in postmenopausal women with mild asymptomatic primary hyperparathyroidism.
    Zanchetta JR; Bogado CE
    J Bone Miner Res; 2001 Jan; 16(1):189-90. PubMed ID: 11149484
    [No Abstract]   [Full Text] [Related]  

  • 28. [Delaying degeneration or promoting regeneration. 2 successful strategies in osteoporosis].
    MMW Fortschr Med; 2004 Mar; 146(10):46. PubMed ID: 15347088
    [No Abstract]   [Full Text] [Related]  

  • 29. [Evidence for the selective estrogen receptor modulator raloxifene: its evolving role in the treatment of osteoporosis].
    Ohta H
    Clin Calcium; 2008 Oct; 18(10):1442-50. PubMed ID: 18830041
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prevention of bone loss in postmenopausal women treated with lasofoxifene compared with raloxifene.
    McClung MR; Siris E; Cummings S; Bolognese M; Ettinger M; Moffett A; Emkey R; Day W; Somayaji V; Lee A
    Menopause; 2006; 13(3):377-86. PubMed ID: 16735934
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Treatment with zoledronic acid ameliorates negative geometric changes in the proximal femur following acute spinal cord injury.
    Shapiro J; Smith B; Beck T; Ballard P; Dapthary M; BrintzenhofeSzoc K; Caminis J
    Calcif Tissue Int; 2007 May; 80(5):316-22. PubMed ID: 17417700
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Evidence of raloxifene on postmenopausal osteoporosis].
    Okano H
    Nihon Rinsho; 2007 Nov; 65 Suppl 9():374-80. PubMed ID: 18161135
    [No Abstract]   [Full Text] [Related]  

  • 33. [Effects of SERMs on bone health. The evaluation of raloxifene treatment for elderly women with osteoporosis using bone turnover markers].
    Hasegawa M; Ichimura S; Satomi K
    Clin Calcium; 2010 Mar; 20(3):413-20. PubMed ID: 20190372
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Association of bone metabolism related genes polymorphisms with the effect of raloxifene hydrochloride on bone mineral density and bone turnover markers in postmenopausal women with osteoporosis.
    Zhang ZL; He JW; Qin YJ; Huang QR; Liu YJ; Hu YQ; Li M
    Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2006 Apr; 23(2):129-33. PubMed ID: 16604479
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Safety and efficacy of teriparatide in elderly women with established osteoporosis: bone anabolic therapy from a geriatric perspective.
    Boonen S; Marin F; Mellstrom D; Xie L; Desaiah D; Krege JH; Rosen CJ
    J Am Geriatr Soc; 2006 May; 54(5):782-9. PubMed ID: 16696744
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Selective estrogen receptor modulators: A possible new treatment of osteoporosis in males.
    Kastelan D; Giljevic Z; Kraljevic I; Korsic M
    Med Hypotheses; 2006; 67(5):1052-3. PubMed ID: 16790322
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Teriparatide: an anabolic drug for the treatment of patients with osteoporosis].
    Lems WF; Hamdy NA; Netelenbos JC
    Ned Tijdschr Geneeskd; 2006 Jan; 150(3):132-7. PubMed ID: 16463613
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy of teriparatide in increasing bone mineral density in postmenopausal women with osteoporosis--an Indian experience.
    Sethi BK; Chadha M; Modi KD; Kumar KM; Mehrotra R; Sriram U
    J Assoc Physicians India; 2008 Jun; 56():418-24. PubMed ID: 18822620
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Assessment of bone quality. Bone quality and osteoporosis treatment].
    Mashiba T
    Clin Calcium; 2008 Mar; 18(3):300-7. PubMed ID: 18310816
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Raloxifene improves bone mass in osteopenic women with primary biliary cirrhosis: results of a pilot study.
    Levy C; Harnois DM; Angulo P; Jorgensen R; Lindor KD
    Liver Int; 2005 Feb; 25(1):117-21. PubMed ID: 15698408
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.